0000950170-23-062936.txt : 20231113 0000950170-23-062936.hdr.sgml : 20231113 20231113160931 ACCESSION NUMBER: 0000950170-23-062936 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPRUCE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001683553 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 812154263 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39594 FILM NUMBER: 231398742 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 740 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (415) 655-4168 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 740 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 sprb-20231113.htm 8-K 8-K
0001683553false00016835532023-11-132023-11-13

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2023

 

 

Spruce Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware

001-39594

81-2154263

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

611 Gateway Boulevard, Suite 740

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 415-655-4168

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

SPRB

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2023, Spruce Biosciences, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2023 and providing corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

 

Description

 

 

 

99.1

Press Release of Spruce Biosciences, Inc., dated November 13, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

SPRUCE BIOSCIENCES, INC.

 

 

 

 

Date:

November 13, 2023

By:

/s/ Samir Gharib

 

 

 

Samir Gharib
President and Chief Financial Officer

 

2

 EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

 

Enrollment Completed in CAHptain-205 Study in Pediatric Classic Congenital Adrenal Hyperplasia (CAH)

 

Target Enrollment Completed in CAHmelia-203 Study in Adult Classic CAH

 

CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024

 

South San Francisco, Calif. – November 13, 2023 – Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

 

“Achieving completion of enrollment milestones in the CAHptain-205 and CAHmelia-203 studies underscores the strong execution of our key clinical objectives and the momentum within our adult and pediatric classic CAH programs,” said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. “We continue to make notable progress in our efforts to advance tildacerfont as a potentially novel therapeutic option for people living with CAH and are eager to report topline data from CAHmelia-203 and CAHptain-205 in the first quarter of 2024.”

 

Recent Corporate Updates
 

•
CAHptain-205 Study in Pediatric Classic CAH Completes Enrollment: Enrollment in the CAHptain study is complete with 30 patients, surpassing the target enrollment of 20 patients. CAHptain is a Phase 2 open-label clinical trial that utilizes a sequential 3 cohort design (cohorts 1 and 2 comprised of adolescent patients 11 to 17 years of age, and cohort 3 comprised of children 2 to 10 years of age) to evaluate the safety, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of tildacerfont in children with classic CAH.

 

•
CAHmelia-203 Study in Adult Classic CAH Completes Target Enrollment: Target enrollment of 72 patients in the company’s CAHmelia-203 clinical trial is complete. CAHmelia-203 is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical trial evaluating the safety and efficacy of tildacerfont in adults with classic CAH and highly elevated levels of androstenedione (A4) at baseline while on stable glucocorticoid dosing. Due to substantial patient interest in CAHmelia-203, final enrollment in the study will exceed its original target of 72 patients.

 

•
CAHmelia-204 Study in Adult Classic CAH on Track to Complete Enrollment in Early Q1 2024: Enrollment in the CAHmelia-204 clinical trial surpassed 75% enrollment and remains on track to complete enrollment in the early first quarter of 2024. CAHmelia-204 is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of tildacerfont in reducing supraphysiologic glucocorticoid use in adult patients with classic CAH.

 

Anticipated Upcoming Milestones

•
Completion of enrollment in the CAHmelia-204 clinical trial in adult classic CAH patients on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 in the early first quarter of 2024
 
•
Topline results from the CAHmelia-203 clinical trial in adult classic CAH patients with highly elevated levels of A4 in the first quarter of 2024
 
•
Topline results from all cohorts in the CAHptain-205 clinical trial in pediatric classic CAH patients in the first quarter of 2024
 

 

 

•
Topline results from the CAHmelia-204 clinical trial in adult classic CAH patients on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 in the third quarter of 2024

 

Third Quarter 2023 Financial Results

 

•
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of September 30, 2023 were $108.0 million. Cash, cash equivalents and investments are expected to allow the company to fund operating and capital expenditures into the first half of 2025.

 

•
Collaboration Revenue: Collaboration revenue for the three and nine months ended September 30, 2023 were $3.1 million and $7.2 million, respectively, compared to nil for the same periods in 2022. The increase in collaboration revenue reflects the partial recognition of the $15.0 million upfront payment the company received in connection with the collaboration and license agreement with Kaken Pharmaceutical.

 

•
Research and Development (R&D) Expenses: R&D expenses for the three and nine months ended September 30, 2023 were $13.5 million and $38.3 million, respectively, compared to $8.8 million and $26.4 million for the same periods in 2022. The overall increase in R&D expenses was primarily related to progressing clinical development of tildacerfont in adult classic CAH, pediatric classic CAH and PCOS.
 
•
General and Administrative (G&A) Expenses: G&A expenses for the three and nine months ended September 30, 2023 were $3.2 million and $9.7 million, respectively, compared to $2.8 million and $8.8 million for the same periods in 2022.
 
•
Total Operating Expenses: Total operating expenses for the three and nine months ended September 30, 2023 were $16.7 million and $48.0 million, respectively, compared to $11.6 million and $35.2 million for the same periods in 2022.
 
•
Net Loss: Net loss for the three and nine months ended September 30, 2023 was $12.4 million and $38.0 million, respectively, compared to $11.4 million and $35.0 million for the same periods in 2022.

 

About Spruce Biosciences

 

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS). To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.


Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the enrollment, results, conduct, progress and timing of Spruce’s clinical trials; the receipt and presentation of topline data from the same; research and development plans; and Spruce’s planned operations, including its expectations regarding operating and capital expenditures being funded into the first half of 2025. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate”, “expect”, “may”, “plan”, “will”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking

 

 

statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

 

 

SPRUCE BIOSCIENCES, INC.

CONDENSED BALANCE SHEETS

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

 

 

 

September 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

98,801

 

 

$

24,487

 

Short-term investments

 

 

9,231

 

 

 

54,590

 

Prepaid expenses

 

 

2,687

 

 

 

3,320

 

Other current assets

 

 

419

 

 

 

1,211

 

Total current assets

 

 

111,138

 

 

 

83,608

 

Right-of-use assets

 

 

1,240

 

 

 

1,400

 

Other assets

 

 

607

 

 

 

640

 

Total assets

 

$

112,985

 

 

$

85,648

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,152

 

 

$

1,426

 

Accrued expenses and other current liabilities

 

 

11,616

 

 

 

9,399

 

Term loan, current portion

 

 

1,622

 

 

 

1,622

 

Deferred revenue, current portion

 

 

7,798

 

 

 

—

 

Total current liabilities

 

 

24,188

 

 

 

12,447

 

Lease liabilities, net of current portion

 

 

1,083

 

 

 

1,261

 

Term loan, net of current portion

 

 

2,113

 

 

 

3,293

 

Other liabilities

 

 

220

 

 

 

161

 

Total liabilities

 

 

27,604

 

 

 

17,162

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 10,000,000 shares authorized and
   no shares issued or outstanding as of September 30, 2023 and December 31, 2022

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value; 200,000,000 shares authorized as of
   September 30, 2023 and December 31, 2022; 40,710,692 and 23,601,004 shares
   issued and outstanding as of September 30, 2023 and December 31, 2022, respectively

 

 

4

 

 

 

3

 

Additional paid-in capital

 

 

272,662

 

 

 

218,354

 

Accumulated other comprehensive loss

 

 

(3

)

 

 

(558

)

Accumulated deficit

 

 

(187,282

)

 

 

(149,313

)

Total stockholders’ equity

 

 

85,381

 

 

 

68,486

 

Total liabilities and stockholders’ equity

 

$

112,985

 

 

$

85,648

 

 

 

 

SPRUCE BIOSCIENCES, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except share and per share amounts)

 

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Collaboration revenue

 

$

3,073

 

 

$

—

 

 

$

7,202

 

 

$

—

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

13,494

 

 

 

8,791

 

 

 

38,332

 

 

 

26,359

 

General and administrative

 

 

3,237

 

 

 

2,766

 

 

 

9,699

 

 

 

8,814

 

Total operating expenses

 

 

16,731

 

 

 

11,557

 

 

 

48,031

 

 

 

35,173

 

Loss from operations

 

 

(13,658

)

 

 

(11,557

)

 

 

(40,829

)

 

 

(35,173

)

Interest expense

 

 

(119

)

 

 

(110

)

 

 

(377

)

 

 

(291

)

Interest and other income, net

 

 

1,423

 

 

 

266

 

 

 

3,237

 

 

 

428

 

Net loss

 

 

(12,354

)

 

 

(11,401

)

 

 

(37,969

)

 

 

(35,036

)

Other comprehensive gain (loss), net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available for sale securities

 

 

52

 

 

 

(28

)

 

 

555

 

 

 

(689

)

Total comprehensive loss

 

$

(12,302

)

 

$

(11,429

)

 

$

(37,414

)

 

$

(35,725

)

Net loss per share, basic and diluted

 

$

(0.30

)

 

$

(0.48

)

 

$

(1.01

)

 

$

(1.49

)

Weighted-average shares of common stock outstanding,
   basic and diluted

 

 

40,710,692

 

 

 

23,560,250

 

 

 

37,751,865

 

 

 

23,515,651

 

 

 

 

Media

Will Zasadny
Evoke Canale
(619) 961-8848
will.zasadny@evokecanale.com
media@sprucebiosciences.com

 

Investors

Samir Gharib
President and CFO

Spruce Biosciences

investors@sprucebiosciences.com

 

 

 EX-101.PRE 3 sprb-20231113_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 sprb-20231113.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 sprb-20231113_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Registrant Name Entity Registrant Name Entity Ex Transition Period Entity Ex Transition Period Document Period End Date Document Period End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number City Area Code City Area Code Pre-commencement Tender Offer Pre-commencement Tender Offer Cover [Abstract] Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity File Number Securities Act File Number Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Title of 12(b) Security Title of 12(b) Security Document Type Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity Registrant Name Spruce Biosciences, Inc.
Entity Central Index Key 0001683553
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39594
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-2154263
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 740
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 415
Local Phone Number 655-4168
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SPRB
Security Exchange Name NASDAQ
XML 7 sprb-20231113_htm.xml IDEA: XBRL DOCUMENT 0001683553 2023-11-13 2023-11-13 0001683553 false 8-K 2023-11-13 Spruce Biosciences, Inc. DE 001-39594 81-2154263 611 Gateway Boulevard Suite 740 South San Francisco CA 94080 415 655-4168 false false false false Common Stock, par value $0.0001 per share SPRB NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sprb-20231113.htm sprb-20231113.xsd sprb-20231113_lab.xml sprb-20231113_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sprb-20231113.htm": { "nsprefix": "sprb", "nsuri": "http://www.sprucebiosciences.com/20231113", "dts": { "inline": { "local": [ "sprb-20231113.htm" ] }, "schema": { "local": [ "sprb-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "sprb-20231113_lab.xml" ] }, "presentationLink": { "local": [ "sprb-20231113_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_a9f0db25-3b5d-4a65-b2cd-c2beb9f19f48", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sprb-20231113.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a9f0db25-3b5d-4a65-b2cd-c2beb9f19f48", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sprb-20231113.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sprucebiosciences.com/20231113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-23-062936-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-062936-xbrl.zip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end